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The beta-amyloid (Aβ) peptide and the Aβ-oligomer receptor, prion protein (PrP), both influence neurogenesis.
Using in vitro murine neural stem cells (NSCs), we investigated whether Aβ and PrP interact to modify neurogenesis.
Aβ imparted PrP-dependent changes on NSC self-renewal, with PrP-ablated and wild-type NSCs displaying increased
and decreased cell growth, respectively. In contrast, differentiation of Aβ-treated NSCs into mature cells was unaffected
by PrP expression. Such marked PrP-dependent differences in NSC growth responses to Aβ provides further evidence
of biologically significant interactions between these two factors and an important new insight into regulation of NSC
self-renewal in vivo.Findings
Introduction
Alzheimer’s disease (AD) is the most common form of
dementia. The core components of the senile plaques
that characterise AD pathologically are beta-amyloid
(Aβ) peptides cleaved from the amyloid precursor pro-
tein (APP). Various Aβ species exist as a result of dif-
fering N- and C-terminal processing sites and these
species can aggregate, forming oligomers that are im-
plicated in Aβ toxicity [1]. Most Aβ species are found
in healthy brain tissue but the relative amounts shift
during AD [2,3]. In health, Aβ1-40 predominates and
during AD Aβ1-42, Aβ4-42 and pyroglutamated Aβ3-
42 (3(pE)-42) are increased [3]. Many other species
also exist with their relative amounts changing during
disease.
Neurogenesis, whilst declining significantly in the adult
organism, continues throughout life. Adult neural stem
cells (NSCs) are confined to specific protected sites within
the brain, including the sub-granular zone (SGZ) of the
dentate gyrus and sub-ventricular zone of the lateral ven-
tricle [4]. Adult NSCs can self-renew and are multipotent;
they can differentiate into cells of any central nervous* Correspondence: stevenjc@unimelb.edu.au; chaigh@unimelb.edu.au
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unless otherwise stated.system lineage. In the brains of AD patients, markers of
neurogenesis are increased [5,6] indicating potential
neurogenic dysregulation or stimulated compensation
for neuronal loss. AD pathology typically begins in the
transentorhinal and entorhinal cortex [7]. This region
lies adjacent to the SGZ and, therefore, NSCs in their
normally protected niche environment may be exposed
to hostile conditions that stimulate them to change their
behaviour [4]. There is significant evidence that Aβ pep-
tides are able to modulate neurogenesis [8-10]. Various
discrepancies exist in the literature as to whether neuro-
genesis is enhanced or suppressed by Aβ exposure,
which is most likely due to the manner in which the Aβ
was prepared (that is, if monomeric, oligomeric or fibril-
lar Aβ species were used) and the model system for
NSC study (for example, in vivo, in vitro, mouse strain);
however, the consensus is in favour of changed NSC be-
haviour following exposure to Aβ species.
Neurogenesis is also modulated by another neurode-
generative disease-associated protein, the prion protein
(PrP) [11,12]. Increased PrP expression is associated with
increased cell cycling at the expense of differentiation
[13]. Recent studies found that PrP is an essential recep-
tor that transduces soluble Aβ1-42 oligomer signals
from the plasma-membrane through the NMDA recep-
tor via the signalling molecule fyn to tau, with this sig-
nalling thought to cause cellular toxicity [14-16]. Based
on the knowledge that both Aβ and PrP can individuallyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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binding partner necessary for the transduction of toxic
signals, we hypothesized that PrP might also transduce
the Aβ peptide signals that alter neurogenesis. The
present study therefore investigated the ability of various
Aβ peptides to modulate in vitro self-renewal and differ-
entiation of adult NSCs harvested from PrP gene-ablated3
Figure 1 Beta-amyloid (Aβ) peptide modulation of neural stem cell (NSC) s
of NSC colonies grown in a collagen matrix with or without Aβ for 21 days
(WT) cells. (C) Neurosphere volume following Aβ treatment calculated from
phase analysis by DNA content; an example experiment from four repeats
*P < 0.05, **P < 0.01, ***P < 0.001.(knock-out (KO)) or from wild-type (WT; normal PrP
expression) mice.
Methods
Aβ-amyloid peptides (China Peptides, China) were pre-
pared as described previously [17]. NSC harvest and
routine culture was as described previously [18,19]. Forelf-renewal is prion protein (PrP) dependent. (A) Representative images
. (B) Neurosphere volume of untreated knock-out (KO) and wild-type
colony diameter (D) and number (E). (F) Flow cytometry cell cycle
is shown. Scale bars = 100 μm. Data are represented as mean ± SEM.
Figure 2 (See legend on next page.)
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Figure 2 Prion protein (PrP) expression has minimal influence on how beta-amyloid (Aβ) affects neural stem cell (NSC) differentiation. Example
plates of western blots for lineage protein markers from knock-out (KO) and wild-type (WT) NSCs treated for either 7 days during differentiation
(A) or 24 hours prior to differentiation for 7 days (B) with 1 μM Aβ. Quantification of the western blots (A & B) for the stem cell marker nestin
(C, F), mature neuronal marker, NF-L (D, G), and GFAP astrocytic marker (E, H). Data are represented as mean ± SEM. Example immunofluorescent
images of NSCs treated with Aβ during (I) and before (J) differentiation with NF-L, GFAP and DAPI nuclear staining shown in red, green and blue
respectively. Scale bars = 15 μm.
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semi-solid gel matrix made with a 2:1 solution of prolifer-
ation medium and collagen. After day 21, neurospheres
were counted and their diameter measured using NIS-
Elements (Nikon Adelaide, Australia) software. Cell cycle
analysis was performed using the Muse Cell Cycle Kit
(Millipore, Bayswater, Victoria AUS). For plate and
blotting assays cells were cultured as an adherent mono-
layer on a 1:1 poly-D-lysine-laminin matrix. Cellular ATP
content was measured using Life Sciences’ ATP assay
(Invitrogen, Mulgrave, Victoria AUS). Immunodetection
methods have been described previously [18-20]. Ex-
panded methodology is provided in Additional file 1.
Results and discussion
Potential Aβ-PrP signalled changes in neurogenesis
were assessed using four Aβ species; Aβ1-40, Aβ1-42,
Aβ4-42 and Aβ3(pE)-42, representing those that are
found ‘normally’ in health and those that have been
linked with cellular toxicity in AD [21,22]. Previous
studies have shown that fibrillar Aβ has no effect on
neurogenesis [23] and soluble oligomeric Aβ42 is toxic;
therefore, Aβ peptides were prepared using an estab-
lished protocol for producing soluble monomeric spe-
cies [17]. One μM Aβ peptide was used based on results
of previous studies that demonstrated this concentration
induced neurogenic effects [24]. No toxicity was observed
at this concentration throughout the duration of the as-
says (Additional file 2).
NSCs are defined by their properties of self-renewal
and differentiation into mature cells of any central ner-
vous system lineage. First we assessed the role of PrP in
modifying NSC self-renewal using a neural colony-
forming assay, which considers both the number of cells
able to form new clonal colonies and the size of the col-
onies formed as an indication of clonal growth rate. As
previously reported, PrP expression positively influenced
NSC self-renewal (two-way analysis of variance (ANOVA),
F = 7.84, P = 0.006, n = 4; Figure 1A & B) [11-13]. To de-
termine whether PrP has a role in transducing Aβ-
mediated changes in NSC growth, WT and KO NSCs
were incubated with the Aβ species described above.
The KO cells showed a significantly greater proliferation
volume when compared with the carrier buffer alone and
equivalently treated WT NSCs for all Aβ species (two-way
ANOVA, F = 53.75, P < 0.001, n = 4, see Additional file 3for complete statistical analyses; Figure 1A & C). The dif-
ference was primarily due to increased diameter of the
Aβ-treated KO colonies (Figure 1D) in contrast to a de-
creased diameter of the WT NSCs exposed to Aβ (two-
way ANOVA, F = 63.43, P < 0.001, n = 4), as the number
of colonies formed was not significantly different be-
tween the WT and KO NSCs (Figure 1E). Proliferation
of Tga20 (PrP overexpressing) NSCs treated with Aβ
showed similar changes to those observed for WT cells,
with no apparent PrP dose-effect at the concentration
of Aβ used (Additional file 4). The presence of PrP did
not confer a greater susceptibility to any one species of
Aβ, indicating that neither the N- nor C-terminal trunca-
tion of Aβ is important for induction of growth changes
or interaction with PrP but that the core of the peptide ap-
pears sufficient.
To further assess differences in NSC growth, Aβ1-42
was used to assess the number of cells in each phase of
the cell cycle 24 hours post-Aβ addition to liquid cul-
ture. More KO cells rested in G0/G1 basally than WT
(two-way ANOVA, F = 22.99, P = 0.003, n = 4) but after
treatment with Aβ the number of KO cells actively cycling
(S, G2/M phases) was significantly increased (two-way
ANOVA for S phase, F = 39.18, P = 0.003, n = 4; for G2/M
phases, F = 24.91, P = 0.003, n = 4; Figure 1F). There was
no significant change for the WT cells, suggesting that the
changes that slow the growth and reduce the diameter of
neurospheres may occur after a longer period of exposure
to Aβ.
NSCs can be induced to differentiate into neurones,
astrocytes and oligodendrocytes. The lineage to which
an individual cell commits is influenced by its extracellu-
lar environment both before and during stimulation to
differentiate. Therefore, NSCs can be manipulated to dif-
ferentiate into a specific mature cell by their environ-
ment. To assess the influence of Aβ-PrP signalling on
NSC differentiation, KO and WT NSCs were either ex-
posed to the Aβ species for 7 days (one treatment only)
whilst induced to differentiate or were exposed to the
Aβ species for 24 hours before induction of differenti-
ation as an Aβ-priming event. When the effect of Aβ on
WT and KO cellular differentiation was considered, no
significant changes were observed in lineage preference
regardless of whether Aβ was present during differenti-
ation (two-way ANOVA for nestin, F = 4.707, P = 0.043
(no individually significant condition), n = 3; for NF-L,
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n = 3; Figure 2A,C-E) or if the cells were primed by treat-
ment before differentiation (two-way ANOVA for nestin,
F = 0.616, P = 0.442, n = 3; for NF-L, F = 0.816, P = 0.377,
n = 3; for GFAP, F = 0.266, P = 0.611, n = 3; Figure 2B,F-H;Figure 3 Beta-amyloid (Aβ) peptide influences on mitochondria and cell m
Saf32 in the proliferating cells treated for 24 hours and in differentiated cel
with 1 μM of each of the Aβ species. (B) Cell metabolism as determined by
outer membrane translocase protein TOMM22. (E) Densitometry of the TO
protein Pin1. (G) Densitometry of Pin1 western blots. (H) Densitometry of p
**P < 0.01. (I) Immunofluorescent images of Aβ1-42 (1 μM; WO2 red) and P
cells for 0 to 60 minutes. Background red staining is endogenous amyloid
these cells; data not shown). DAPI nuclear staining is shown in blue, ScaleAdditional file 5). However some morphological changes
in WT astrocytes treated with Aβ1-42, Aβ4-42 and
Aβ3(pE)-42 were observed when cells were treated during,
but not when exposed before, differentiation, indicating
an influence of the C-terminal two residues (Figure 2I,J).etabolism. (A) PrP expression in wild-type (WT) cells detected with
ls treated for 7 days. (B-I) Proliferating cells were treated for 24 hours
MTS. (C) Cellular ATP content. (D) Western blots for the mitochondrial
MM22 detection in Aβ-treated cells. (F) Western blots for the cell cycle
53 western blots. Data are represented as mean ± SEM. *P < 0.05,
rP (03R19 green) incubation with knock-out (KO) and WT neural stem
precursor protein reactivity (endogenous Aβ cannot be detected in
bars = 25 μm.
Figure 4 Schematic of beta-amyloid (Aβ) peptide influences on
prion protein (PrP) knock-out (KO) and wild-type (WT) neural stem
cell (NSC) growth. Representation of NSC neurosphere formation
without Aβ and when Aβ is added to KO and WT NSCs.
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WT cells throughout 7 days of Aβ treatment may indicate
that developing astrocytic maturity and the changes in cel-
lular protein expression associated may be required for ac-
tivation of Aβx-42 signalling pathways.
With the most striking Aβ observations relating to op-
posing changes in self-renewal of the KO and WT cells, it
was next considered how these effects might be trans-
duced. Contrary to previous reports [25,26], in the time
frames examined no significant influences of Aβ on PrP
expression levels were measurable (Figure 3A; Additional
file 6). Whilst chronic exposure may reduce expression
over time, in the context of the experiments performed,
PrP was present to perform its function.
Changes in the rate of cell cycling are likely to require
energy. Therefore, markers of cellular metabolism and
mitochondrial function, as well as cell cycle, were com-
pared in WT and KO NSCs following Aβ treatment. For-
mazan metabolism was significantly increased in NSC KO
cells compared with the WT cells when cells were treated
with Aβ1-40 and Aβ4-42 (two-way ANOVA, F = 16.55,
P < 0.001, n = 3, see Additional file 5 for basal data and
Additional file 7 for full statistical analyses; Figure 3B).
Cellular ATP levels were generally unchanged between
the KO and WT NSCs, only showing a decrease in WT
cells treated with Aβ4-42 (two-way ANOVA, F = 5.95,
P = 0.021, n = 4; Figure 3C). This steady-state ATP
measurement does not preclude increased production
balanced by increased use. Contrary to decreased growth,
TOMM22, a mitochondrial outer membrane translocase,
was increased in WT cells when treated with Aβ1-40,
Aβ4-42, and Aβ3(pE)-42 (two-way ANOVA, F = 16.45,
P < 0.001, n = 3; Figure 3D,E). Potentially, this might
indicate that Aβ can exert an effect on mitochondria
signalled through PrP that could be detrimental to
their function, thus limiting growth. The cell cycle
marker Pin1 has also been shown to protect against
tau hyperphosphorylation and subsequent changes to
the cellular cytoskeleton [27]. Pin1 was globally in-
creased in the Aβ-treated WT compared with the KO
cells, although only the Aβ4-42 condition was individu-
ally significant (two-way ANOVA, F = 21.98, P < 0.001,
n = 4; Figure 3F,G). The overall increase in Pin1 could re-
flect a failed effort to increase cell cycling in these cells or
might represent a cellular protective response against Aβ.
p53 is linked with cell cycle and also with cell death.
When activated, the half-life of this protein increases
resulting in increased protein detection over time. No
changes in p53 protein were observed upon treatment
with Aβ in either the KO or WT NSCs (Figure 3H). We
additionally considered other previously PrP-linked Aβ
signalling pathways (fyn, GSK-3β and calcium) finding no
changes in Aβ-induced responses that relate to PrP ex-
pression (Additional file 8).When the localisation of Aβ added to cells was consid-
ered relative to PrP, surface staining of Aβ was observed
to be more intense on the WT cells after 1 hour and PrP
surface staining appeared less with greater signal inside
the cells (Figure 3I). These findings are consistent with
previous studies that have shown Aβ preferentially binds
to cells expressing PrP causing internalisation [28] and
also supports the hypothesis that Aβ stimulates different
pathways in KO and WT cells.
It remains to be determined how NSCs are affected by
PrP-linked Aβ signalling in vivo, where the context of
their support cells and scaffold may lead to more diverse
outcomes. However, the clear responses of the cells cul-
tured in vitro indicates that sufficient cellular machinery
and environmental factors to transduce PrP-Aβ signal-
ling cascades are present. The details of these pathways
will be revealed by future investigation, but it is of inter-
est that the classical Aβ signalling pathways evaluated
here were unaffected. Hypothetically, as PrP-Aβ studies
to date were performed in neuronal cultures or mice,
different pathways could be engaged in NSCs and post-
mitotic neurones or, alternatively, differing pathways
may be activated when Aβ levels reach toxic concentra-
tions. Furthermore, during sporadic AD, brain PrP ex-
pression reduces [26], inversely correlating with Aβ
burden. Reduced PrP expression (akin to KO NSCs) may
Collins et al. Stem Cell Research & Therapy  (2015) 6:60 Page 7 of 8permit Aβ stimulation of NSC proliferation, resulting
in the increased neurogenic markers seen in AD brain
tissue [5,6].
Conclusions
This study has validated the hypothesis that the previ-
ously observed, Aβ-signalled changes in neurogenesis
can be transduced through the Aβ-oligomer receptor,
PrP. In addition, we demonstrated that this signalling is
more complex than PrP acting as a simple ‘on’ or ‘off ’
switch for the pathway (summarised in Figure 4). Our
data indicate that: i) congruous with studies using neur-
onal cells and mice [16,29], differing Aβ pathways are
activated in the NSCs depending upon the presence and
absence of PrP; ii) Aβ-PrP signalling inhibits NSC pro-
liferation signals, although possibly monomeric forms
of Aβ act in contrast to the synaptotoxic soluble oligo-
mers; and iii) variations in the basal expression levels of
PrP might also account for some of the previous variability
in, and disagreements over, NSC growth responses to Aβ.
This dynamic and complex interplay of key factors regu-
lating NSC growth provides significant new insight into
the control of NSC self-renewal and further evidence of
biologically significant interactions between Aβ peptides
and PrP.
Additional files
Additional file 1: Expanded methods.
Additional file 2: Aβ toxicity.
Additional file 3: Statistical analyses of data presented in Figure 1.
Additional file 4: NCFA results comparing Tga20 with KO and WT
NSCs and baseline data.
Additional file 5: Baseline comparisons of KO and WT cells.
Additional file 6: PrP expression level changes in WT cells treated
with Aβ.
Additional file 7: Statistical analyses of data presented in Figure 3.
Additional file 8: Further signalling pathways examined in cells
treated with Aβ.
Abbreviations
Aβ: beta-amyloid; Aβ3(pE)-42: pyroglutamated Aβ3-42; AD: Alzheimer’s
disease; ANOVA: analysis of variance; KO: knock-out; NSC: neural stem cell;
PrP: prion protein; SGZ: subgranular zone; WT: wild type.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CLH, CT, QXL, TMR and BR performed experiments. CLH, SJC and CT analysed
data. CLH, SJC, QXL, VL, SCD and VAL designed experiments. CLH designed
the study and wrote the paper. All authors have read and approved the final
version of the manuscript.
Acknowledgements
The authors would like to acknowledge Professor Colin Masters for his
ongoing support and thank Dr Theo Mantamadiotis and Ms Gulay Filiz for
their assistance with the cell cycle flow cytometry. This work was supported
by an NHMRC program grant (#628946) and the Victorian Government’sOperational Infrastructure Support program. SJC is supported by an NHMRC
Practitioner Fellowship (#APP100581), SCD by an ARC Future Fellowship
(FT110100199) and TMR by an Alzheimer’s Australia fellowship.
Author details
1Department of Pathology, The University of Melbourne, Melbourne Brain
Centre, Melbourne, VIC 3010, Australia. 2Department of Medicine, Royal
Melbourne Hospital, The University of Melbourne, Melbourne, VIC 3010,
Australia. 3Florey Institute of Neuroscience and Mental Health, The University
of Melbourne, Melbourne, VIC 3010, Australia. 4The Florey Department of
Neuroscience and Mental Health, The University of Melbourne, Melbourne,
VIC 3010, Australia.
Received: 23 October 2014 Revised: 27 January 2015
Accepted: 25 March 2015
References
1. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic
plasticity and behavior. Behav Brain Res. 2008;192:106–13.
2. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G,
Zetterberg H, et al. Mass spectrometric characterization of brain amyloid
beta isoform signatures in familial and sporadic Alzheimer’s disease. Acta
Neuropathol. 2010;120:185–93.
3. Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, et al.
Overlapping profiles of Abeta peptides in the Alzheimer’s disease and
pathological aging brains. Alzheimers Res Ther. 2012;4:18.
4. Lazarov O, Marr RA. Neurogenesis and Alzheimer’s disease: at the
crossroads. Exp Neurol. 2010;223:267–81.
5. Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, et al. Increased
hippocampal neurogenesis in Alzheimer’s disease. Proc Natl Acad Sci U S A.
2004;101:343–7.
6. Gomez-Nicola D, Suzzi S, Vargas-Caballero M, Fransen NL, Al-Malki H,
Cebrian-Silla A, et al. Temporal dynamics of hippocampal neurogenesis in
chronic neurodegeneration. Brain. 2014;137:2312–28.
7. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes.
Acta Neuropathol. 1991;82:239–59.
8. Kanemoto S, Griffin J, Markham-Coultes K, Aubert I, Tandon A, George-Hyslop PS,
et al. Proliferation, differentiation and amyloid-beta production in neural
progenitor cells isolated from TgCRND8 mice. Neuroscience.
2014;261:52–9.
9. Lee IS, Jung K, Kim IS, Park KI. Amyloid-beta oligomers regulate the
properties of human neural stem cells through GSK-3beta signaling. Exp
Mol Med. 2013;45:e60.
10. Zheng M, Liu J, Ruan Z, Tian S, Ma Y, Zhu J, et al. Intrahippocampal
injection of Abeta1-42 inhibits neurogenesis and down-regulates
IFN-gamma and NF-kappaB expression in hippocampus of adult mouse
brain. Amyloid. 2013;20:13–20.
11. Peralta OA, Huckle WR, Eyestone WH. Expression and knockdown of cellular
prion protein (PrPC) in differentiating mouse embryonic stem cells.
Differentiation. 2011;81:68–77.
12. Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD. Prion protein
(PrPc) positively regulates neural precursor proliferation during
developmental and adult mammalian neurogenesis. Proc Natl Acad Sci
U S A. 2006;103:3416–21.
13. Lee YJ, Baskakov IV. Treatment with normal prion protein delays
differentiation and helps to maintain high proliferation activity in human
embryonic stem cells. J Neurochem. 2010;114:362–73.
14. You H, Tsutsui S, Hameed S, Kannanayakal TJ, Chen L, Xia P, et al. Abeta
neurotoxicity depends on interactions between copper ions, prion protein,
and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A.
2012;109:1737–42.
15. Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA,
et al. The complex PrP(c)-Fyn couples human oligomeric Abeta with
pathological tau changes in Alzheimer’s disease. J Neurosci.
2012;32:16857–71a.
16. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, et al.
Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein
activates Fyn to impair neurons. Nat Neurosci. 2012;15:1227–35.
17. McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, et al. The
Caenorhabditis elegans A beta 1–42 model of Alzheimer disease
predominantly expresses A beta 3–42. J Biol Chem. 2009;284:22697–702.
Collins et al. Stem Cell Research & Therapy  (2015) 6:60 Page 8 of 818. Haigh CL, McGlade AR, Lewis V, Masters CL, Lawson VA, Collins SJ. Acute
exposure to prion infection induces transient oxidative stress progressing to
be cumulatively deleterious with chronic propagation in vitro. Free Radic
Biol Med. 2011;51:594–608.
19. Sinclair L, Lewis V, Collins SJ, Haigh CL. Cytosolic caspases mediate
mislocalised SOD2 depletion in an in vitro model of chronic prion infection.
Dis Model Mech. 2013;6:952–63.
20. Haigh CL, Lewis VA, Vella LJ, Masters CL, Hill AF, Lawson VA, et al. PrPC-related
signal transduction is influenced by copper, membrane integrity and the alpha
cleavage site. Cell Res. 2009;19:1062–78.
21. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, et al.
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated
amyloid-beta. Nature. 2012;485:651–5.
22. Bouter Y, Dietrich K, Wittnam JL, Rezaei-Ghaleh N, Pillot T, Papot-Couturier S,
et al. N-truncated amyloid beta (Abeta) 4–42 forms stable aggregates and
induces acute and long-lasting behavioral deficits. Acta Neuropathol.
2013;126:189–205.
23. Heo C, Chang KA, Choi HS, Kim HS, Kim S, Liew H, et al. Effects of the
monomeric, oligomeric, and fibrillar Abeta42 peptides on the proliferation
and differentiation of adult neural stem cells from subventricular zone. J
Neurochem. 2007;102:493–500.
24. Haughey NJ, Liu D, Nath A, Borchard AC, Mattson MP. Disruption of
neurogenesis in the subventricular zone of adult mice, and in human
cortical neuronal precursor cells in culture, by amyloid beta-peptide:
implications for the pathogenesis of Alzheimer’s disease. Neuromolecular
Med. 2002;1:125–35.
25. Whitehouse IJ, Jackson C, Turner AJ, Hooper NM. Prion protein is reduced in
aging and in sporadic but not in familial Alzheimer’s disease. J Alzheimers
Dis. 2010;22:1023–31.
26. Whitehouse IJ, Miners JS, Glennon EB, Kehoe PG, Love S, Kellett KA, et al.
Prion protein is decreased in Alzheimer’s brain and inversely correlates with
BACE1 activity, amyloid-beta levels and Braak stage. PLoS One.
2013;8:e59554.
27. Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, et al. Role of the prolyl
isomerase Pin1 in protecting against age-dependent neurodegeneration.
Nature. 2003;424:556–61.
28. Rushworth JV, Griffiths HH, Watt NT, Hooper NM. Prion protein-mediated
toxicity of amyloid-beta oligomers requires lipid rafts and the transmembrane
LRP1. J Biol Chem. 2013;288:8935–51.
29. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, et al.
Memory impairment in transgenic Alzheimer mice requires cellular prion
protein. J Neurosci. 2010;30:6367–74.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
